Equity

Medtronic·Balance Sheet Statement·13 metrics

Breakdown

Metric	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26	Q3 '26
Total liabilities and stockholders' equity	$90B	$89.7B	$90B	$90B	$91.7B	$91B	$91.3B	$91.5B
Total stockholders' equity	$50.2B	$47.9B	$48.5B	$49.4B	$48B	$47.9B	$48.7B	$49B
Retained earnings	$30.4B	$30.5B	$30.9B	$31.3B	$31.5B	$31.6B	$32.1B	$32.3B
Additional paid-in capital	$23.1B	$20.8B	$20.8B	$20.9B	$20.8B	$20.9B	$20.9B	$21B
Accumulated other comprehensive income (loss)	-$3.3B	-$3.4B	-$3.3B	-$2.8B	-$4.3B	-$4.6B	-$4.3B	-$4.3B
Common stock	0	2.6B	2.6B	2.6B	2.6B	2.6B	2.6B	2.6B
Common Stock Shares Issued	1.3B	1.3B	1.3B	1.3B	1.3B	1.3B	1.3B	1.3B
Noncontrolling interests	$206M	$213M	$222M	$228M	$232M	$240M	$204M	$211M
Unrealized Losses on Investments (Before Tax)	$252M	$174M	$138M	$134M	$100M	$84M	$57M	$55M
Unrealized Gains on Investments	$7M	$18M	$22M	$15M	$26M	$33M	$72M	$54M
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	$238M	$162M	$128M	$125M	$91M	$75M	$48M	$47M
Common Stock Par Value Per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$0	$0	$0	$0	$0	$0	$0	$0